O01 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial
Weiss K, Schilsky M, Czlonkowska A, Askari F, Ala A, Ferenci P, Ott P, Abdurakhmanov D, Szalay F, Socha P, Shimizu N, Bronstein J, Bega D, Hahn S, Swenson E, Chen Y, Poujois A. O01 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial. 2022, a1-a1. DOI: 10.1136/gutjnl-2022-basl.1.Peer-Reviewed Original ResearchGS001 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial
Weiss K, Schilsky M, Czlonkowska A, Askari F, Ala A, Ferenci P, Ott P, Abdurakhmanov D, Szalay F, Socha P, Shimizu N, Bronstein J, Bega D, Hahn S, Swenson E, Chen Y, Poujois A. GS001 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial. Journal Of Hepatology 2022, 77: s1. DOI: 10.1016/s0168-8278(22)00428-7.Peer-Reviewed Original Research